about
Disagreements with implications: diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement.Generating genius: how an Alzheimer's drug became considered a 'cognitive enhancer' for healthy individuals.Food addiction and its impact on weight-based stigma and the treatment of obese individuals in the U.S. and Australia.Researchers' perspectives on scientific and ethical issues with transcranial direct current stimulation: An international survey.The is and ought of the Ethics of Neuroenhancement: Mind the Gap.Navigating the enhancement landscape. Ethical issues in research on cognitive enhancers for healthy individuals.Australian University Students' Coping Strategies and Use of Pharmaceutical Stimulants as Cognitive EnhancersThe value and pitfalls of speculation about science and technology in bioethics: the case of cognitive enhancement.The Hidden Ethics Curriculum in Two Canadian Psychiatry Residency Programs: A Qualitative Study.Complementary and Alternative Medicine in the Context of Earlier Diagnoses of Alzheimer's Disease: Opening the Conversation to Prepare Ethical Responses.Patient Preferences May Be Indicative of Normative Issues in Dementia Research.A prospectus for ethical analysis of ageing individuals' responsibility to prevent cognitive decline.Contextualized Autonomy and Liberalism: Broadening the Lenses on Complementary and Alternative Medicines in Preclinical Alzheimer's Disease.The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises?Ethical issues raised by a ban on the sale of electronic nicotine devices.The brain disease model of addiction: challenging or reinforcing stigma?--Authors' reply.Brain disease model of addiction: misplaced priorities?Expectations regarding cognitive enhancement create substantial challenges.Nuances in the ethical regulation of electronic nicotine delivery systems.Responding to requests from adult patients for neuroenhancements: guidance of the ethics, law and humanities committee.How Research on Stakeholder Perspectives Can Inform Policy on Cognitive EnhancementSurveillance Medicine in the DigitalEra: Lessons From Addiction TreatmentNon-medical prescription stimulant use to improve academic performance among Australian university students: prevalence and correlates of useStakeholder perspectives and reactions to "academic" cognitive enhancement: Unsuspected meaning of ambivalence and analogiesBeyond Flourishing: Intersecting Uses and Interests in the Neurotechnology Marketplace
P50
Q33478729-C18051B2-9A3C-41E7-A68D-1D86B17A35A3Q33777577-AC536322-9674-47A9-8309-D98A04A05492Q34578156-7B975498-1223-4491-8DDD-EDC2D25B16E3Q35727708-770CEF21-7718-4626-8DB0-466CE5852FDFQ36441885-2C6BFCA0-2E09-43FC-A53E-045BFD533FD1Q36594188-E6F44EF2-265C-4FD3-A041-72A187818623Q36633000-4EF845A4-3F84-4BFF-A64A-E593FF7055DEQ38176831-7742214D-BC6F-4A7D-BED2-79DE0C37921AQ38647944-10A440DD-4940-40DC-8C7D-9A50DA704B8BQ38719653-569FFF24-EF76-4D6B-984C-0DEB2997385EQ38760644-EDF0ED68-1C6B-4C52-B937-7E48AD3224F4Q47252654-43379E92-FBC2-4035-A6FA-A98A859FE2D8Q47330975-B136DE1D-4DB7-486E-8931-3BC0CD9E8690Q48009927-6D8EDFC5-A61D-4A4C-A189-7C0C8719D196Q48041557-F1B0C429-BAE5-47C1-96AF-0065EA414544Q50791444-8A6CAFE7-A9BB-4CFE-BA18-83CC0755C589Q51825028-0AF8A4AC-0F24-480A-881D-2B9E7F8A2C99Q51865344-AB23C252-42E9-45FD-9FCE-2B19AF8AE93AQ52307263-EB1F8DEC-388D-402A-B051-BDF126234503Q53076636-552BDF96-5C8F-4439-ADFB-1FE536466EBEQ57988612-7EE6B66A-8BFB-49A7-85A2-9F2A7642FC66Q57989391-A9C77F58-CC55-4AB9-9CCF-60E10402C6D5Q59336572-57BC9366-E5E1-465E-95D5-B62C6536B185Q87039344-5B2669E8-3B6E-49B4-9A9E-9E2EAD221382Q90900930-612A0B58-7E9C-46C7-B49C-556B60B31F6E
P50
description
researcher ORCID ID = 0000-0003-3809-8229
@en
name
Cynthia Forlini
@ast
Cynthia Forlini
@en
Cynthia Forlini
@es
Cynthia Forlini
@nl
type
label
Cynthia Forlini
@ast
Cynthia Forlini
@en
Cynthia Forlini
@es
Cynthia Forlini
@nl
prefLabel
Cynthia Forlini
@ast
Cynthia Forlini
@en
Cynthia Forlini
@es
Cynthia Forlini
@nl
P1153
33367648800
P31
P496
0000-0003-3809-8229